TrialBMC cancer2018

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.

Thomas J Ettrich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.